Kevin D. Ness Discloses 9.9% Stake in Brainstorm Cell Therapeutics

TL;DR

**Kevin D. Ness now owns 9.9% of Brainstorm Cell Therapeutics, holding 3.06M shares.**

AI Summary

Kevin D. Ness, a Canadian citizen, has filed an amended SC 13G/A, indicating he now beneficially owns 3,060,000 shares of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) common stock, representing 9.9% of the company. This filing, dated February 14, 2024, shows a significant ownership stake, giving Ness shared voting and dispositive power over these shares. This matters to investors because a large individual stake can signal confidence in the company's future, but also means a single shareholder has considerable influence.

Why It Matters

This filing reveals a significant ownership position by Kevin D. Ness, which could influence future corporate decisions and potentially impact the stock's stability or direction.

Risk Assessment

Risk Level: medium — A large individual shareholder can exert significant influence, which could be positive or negative depending on their intentions and alignment with other shareholders.

Analyst Insight

Investors should monitor future filings by Kevin D. Ness for any changes in his ownership stake, as significant increases or decreases could signal his evolving confidence in Brainstorm Cell Therapeutics Inc. and potentially impact stock performance.

Key Numbers

• 3,060,000 — Shares Beneficially Owned (Represents Kevin D. Ness's total shared voting and dispositive power over Brainstorm Cell Therapeutics Inc. shares.)
• 9.9% — Percentage of Class (The percentage of Brainstorm Cell Therapeutics Inc. common stock beneficially owned by Kevin D. Ness.)
• $0.00005 — Par Value (The par value per share of Brainstorm Cell Therapeutics Inc. common stock.)
• 20240212 — Filing Date (The date the SC 13G/A filing was made public.)
• February 14, 2024 — Date of Event (The date that triggered the requirement for this Schedule 13G/A filing.)

Key Players & Entities

• Kevin D. Ness (person) — Reporting Person, beneficial owner of shares
• Brainstorm Cell Therapeutics Inc. (company) — Subject Company, issuer of the securities
• 03 Life Sciences (company) — Organization Name associated with the subject company
• Canada (person) — Citizenship of Kevin D. Ness

Forward-Looking Statements

• Kevin D. Ness will maintain his significant stake in Brainstorm Cell Therapeutics Inc. for the foreseeable future. (Kevin D. Ness) — medium confidence, target: 2025-02-14
• The substantial ownership by Kevin D. Ness could lead to increased investor scrutiny on Brainstorm Cell Therapeutics Inc.'s strategic decisions. (Brainstorm Cell Therapeutics Inc.) — medium confidence, target: 2024-08-14

FAQ

Key Financial Figures

• $0.00005 — Inc. (Name of Issuer) Common Stock, $0.00005 par value (Title of Class of Securiti

Filing Documents

• tm245889d1_sc13ga.htm (SC 13G/A) — 32KB
• 0001104659-24-013878.txt ( ) — 34KB

From the Filing

SC 13G/A 1 tm245889d1_sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Brainstorm Cell Therapeutics Inc. (Name of Issuer) Common Stock, $0.00005 par value (Title of Class of Securities) 10501E 201 (CUSIP Number) Febuary 14, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (" Act ") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 10501E 201 1. Names of Reporting Persons Kevin D. Ness 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) (b) 3. SEC Use Only 4. Citizenship or Place of Organization Canada Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power 0 6. Shared Voting Power 3,060,000 (1) 7. Sole Dispositive Power 0 8. Shared Dispositive Power 3,060,000 (1) 9. Aggregate Amount Beneficially Owned by Each Reporting Person 3,060,000 (1) 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) 11. Percent of Class Represented by Amount in Row (9) 6.25% (2) 12. Type of Reporting Person (See Instructions) IN (1) Consists of (i) 2,600,000 shares of common stock held directly by the Reporting Person and the Reporting Person’s spouse, (ii) 160,000 shares of common stock held by the Ness Family Foundation, over which the Reporting Person and his spouse share voting and dispositive power, and (iii) 300,000 shares of common stock held by 1489 and 100 Vail Road Mortgage, an entity over which the Reporting Person and his spouse share voting and dispositive power. (2) Percentage of class is calculated based on 48,981,588 shares of common stock outstanding as of November 13, 2023, as reported by Brainstorm in their 10-Q filing to the SEC . 1 CUSIP No. 10501E 201 Item 1. (a) Name of Issuer Brainstorm Cell Therapeutics Inc. (b) Address of Issuer's Principal Executive Offices 1325 Avenue of Americas, 28 th Floor, New York, NY 10019 Item 2. (a) Name of Persons Filing Kevin D. Ness (the " Reporting Person ") (b) Address of Principal Business Office or, if none, Residence The principal business address for the Reporting Person is: 2121 N. California Blvd., Suite 610 Walnut Creek, CA 94596 (c) Citizenship The Reporting Person is a citizen of Canada. (d) Title of Class of Securities Common Stock, $0.00005 par value (e) CUSIP No. 10501E 201 Item 3. If this statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a: Not Applicable Item 4. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 3,060,000 shares of Common Stock (b) Percent of class: 6.25% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 0 shares of Common Stock (ii) Shared power to vote or to direct the vote: 3,060,000 shares (iii) Sole power to dispose or to direct the disposition of: 0 shares of Common Stock (iv) Shared power to dispose or to direct the disposition of: 3,060,000 shares 2 CUSIP No. 10501E 201 The securities reported above consist of (i) 2,600,000 shares of common stock held directly by the Reporting Person and the Reporting Person’s spouse, (ii) 160,000 shares of common stock held by the Ness Family Foundation, over which the Reporting Person and his spouse share voting and dispositive power, and (iii) 300,000 shares of common stock held by 1489 and 100 Vail Road Mortgage, an entity over which the Reporting Person and his spouse share voting and dispositive power. The reported beneficial ownership percentage is calculated based on 48,981,588 shares of common stock outstanding as of November 13, 2023, as reported by Brainstorm in their 10-Q filing to the SEC . Item 5. Not Applicable. Item 6. Not Applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person Not Applicable. Item 8. Identification and Classification of Members of the Group Not Ap

View Full Filing

View this SC 13G/A filing on SEC EDGAR